Javaid, H; Barberis, A; Chervova, O; Nassiri, I; Voloshin, V; Sato, Y; Ogawa, S; ... Humphrey, TC; + view all Javaid, H; Barberis, A; Chervova, O; Nassiri, I; Voloshin, V; Sato, Y; Ogawa, S; Fairfax, B; Buffa, F; Humphrey, TC; - view fewer (2023) A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation. BMC Cancer , 23 (1) , Article 721. 10.1186/s12885-023-11162-0.

Preview

PDF s12885-023-11162-0.pdf - Published Version Download (3MB) | Preview

Abstract

SETD2-dependent H3 Lysine-36 trimethylation (H3K36me3) has been recently linked to the deposition of de-novo DNA methylation. SETD2 is frequently mutated in cancer, however, the functional impact of SETD2 loss and depletion on DNA methylation across cancer types and tumorigenesis is currently unknown. Here, we perform a pan-cancer analysis and show that both SETD2 mutation and reduced expression are associated with DNA methylation dysregulation across 21 out of the 24 cancer types tested. In renal cancer, these DNA methylation changes are associated with altered gene expression of oncogenes, tumour suppressors, and genes involved in neoplasm invasiveness, including TP53, FOXO1, and CDK4. This suggests a new role for SETD2 loss in tumorigenesis and cancer aggressiveness through DNA methylation dysregulation. Moreover, using a robust machine learning methodology, we develop and validate a 3-CpG methylation signature which is sufficient to predict SETD2 mutation status with high accuracy and correlates with patient prognosis.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item